Autologous NK cell (MD Anderson Cancer Center)

自体NK细胞(MD Anderson Cancer Center)

Report date: 2022/09/06 18:12:16

Base Information

Drug NameAutologous NK cell (MD Anderson Cancer Center)
Drug Alias NameiC9/CAR.19/IL15-transduced CB-NK cellsiC9/CAR.19/IL15-transduced cord blood-NK cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionCell replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBellicum Pharmaceuticals IncThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLymphoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A